NewAmsterdam Pharma Co Analyst Price Targets

Wall Street analyst price targets and consensus rating for NewAmsterdam Pharma Co (NAMS).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$46Upside to Avg. PT+134.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$50→$42
Sep 8, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	Maintained	Buy	$52
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$51→$50
Jun 30, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$47→$51
Feb 19, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$41→$45
Feb 18, 2026	Needham	Serge Belanger	PT Raise	Buy	$46→$48
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$44→$47
Dec 16, 2025	Stifel	James Condulis	PT Raise	Buy	$44→$50
Dec 2, 2025	Goldman Sachs	Asad Haider	PT Raise	Neutral	$30→$37
Nov 6, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$39→$44
Nov 5, 2025	Needham	Serge Belanger	PT Raise	Buy	$40→$46
Oct 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$52
Oct 17, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$42→$50
Aug 25, 2025	Wells Fargo	Yanan Zhu	Initiate	Overweight	$45
Aug 7, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$38→$39
Jul 17, 2025	Goldman Sachs	Asad Haider	Initiate	Neutral	$27
Jun 17, 2025	Citigroup	Geoff Meacham	Initiate	Buy	$42
Jun 12, 2025	Needham	Serge Belanger	Maintained	Buy	$40
Jun 10, 2025	Stifel	James Condulis	Initiate	Buy	$44
May 8, 2025	Needham	Serge Belanger	PT Cut	Buy	$42→$40

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $52 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $41 to $45.

Benzinga Newsdesk

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co

Benzinga Insights

NewAmsterdam Pharma Co NV

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

NewAmsterdam Pharma Co Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

PRO
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

PRO
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co

People Also Watch

People Also Watch

NewAmsterdam Pharma Co NV

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

NewAmsterdam Pharma Co Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

PROHC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

PRORBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

PRORBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

PROGuggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

PRO
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

PRO
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45